Month: June 2025

ATHENS, Greece, June 06, 2025 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that through a separate wholly-owned subsidiary, it has entered into a time charter contract with Stone Shipping Ltd, for one of its Ice Class Panamax dry bulk vessels, the m/v Atalandi. The gross charter rate is US$9,000 per day for the first thirty-five (35) days of the charter period and US$10,100 per day for the balance period of the time charter, in each case minus a 5.00% commission paid to third parties, for a period until minimum June 15, 2026 up to maximum August 15, 2026. The charter is expected to commence on June 9, 2025. The “Atalandi” is a 77,529 dwt Ice Class Panamax dry bulk vessel built in 2014. The...

SINGAPORE, June 06, 2025 (GLOBE NEWSWIRE) — Davis Commodities (DTCK) has announced the successful approval of a $30 million fundraising plan. According to the company’s latest strategy, a significant portion of the funds will be allocated to establishing Bitcoin reserves, aiming to enhance asset allocation, improve operational flexibility, and strengthen counterparties’ confidence in the company. Davis Commodities stated that Bitcoin, often referred to as the “digital gold against inflation,” has become a globally influential cryptocurrency with strong value as a store of wealth and significant appreciation potential. With its capped supply of 21 million coins, Bitcoin possesses inherent scarcity, making it a highly desirable asset in today’s economic landscape. As Bitcoin increasingly becomes a key asset in global...

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patientsNo new safety signals were observed New data presented at late-breaking session at the European Renal Association Congress Marketing applications for EMPAVELI are under review with the FDA and EMAWALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress. In the VALIANT study, EMPAVELI demonstrated a statistically significant...

Receives Notice of Failure to File Interim Financial Statements in Violation of Nasdaq Listing Rules SINGAPORE, June 06, 2025 (GLOBE NEWSWIRE) — JBDI Holdings Limited (“JBDI” or the “Company”) (Nasdaq: JBDI), today announced that it has received notice (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) on June 3, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), and that the Company was therefore in compliance with the Nasdaq Capital Market’s listing requirements. The Company had previously been notified by Nasdaq on December 12, 2024, that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Listing Rule 5450(a)(1) of The Nasdaq Stock Market (“Bid Price...

Chrysler Turns 100! Chrysler Brand Shares 1,500-plus 100th Birthday Group Photo Honoring Employees, Announces Century of Innovation Summer Celebration Events As It Looks to Next 100 YearsMore than 1,500 Stellantis employees come together for a group birthday photo at the Chrysler Technology Center campus, honoring those who have made 100 years of Chrysler possible Group photo participants also help commemorate the Chrysler Century of Innovation with the dedication of a unique time-capsule replica of Walter P. Chrysler’s toolbox The replica toolbox time capsule encased with memorabilia and artifacts, including historic Chrysler brand and vehicle badges, brochures, merchandise, vehicle sketches, and a clever nod to Walter P. Chrysler Toolbox time capsule also includes a list of names of those participating in the group photo, as well...

Irvine, CA, June 06, 2025 (GLOBE NEWSWIRE) — Foxx Development Holdings Inc. (“Foxx Development” or “Company”) (Nasdaq: FOXX), a leading provider of consumer electronics and integrated Internet-of-Things (IoT) solutions for retail and institutional clients, today announced that the Company will be included in the Russell Microcap® Index following FTSE Russell’s preliminary 2025 annual reconstitution list. Foxx is among the telecommunications companies slated to join the list, representing a significant milestone for the Company. The newly reconstituted indexes will take effect after U.S. market close on June 27. The Russell Microcap® Index is completely reconstituted annually to ensure new and growing equities are reflected and companies included continue to reflect appropriate capitalization and value characteristics. After...

Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will participate in a Virtual Fireside Chat hosted by Chardan Capital Markets, LLC on Monday, June 9, 2025 at 3:00 PM ET. For the fireside chat, Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer, Kanya Rajangam, M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer, and Jay Cross, Chief Financial Officer of Senti Biosciences will join Chardan senior...

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a dozen programs from discovery into clinical development, and he has developed multiple pioneering approved medicines such...